Alzheimer's disease drug
Executive Summary
Sen. Pell (D-R.I.) introduced legislation to require the National Institute on Aging to provide $2 mil. per year for a three-year study of tacrine (tetrahydroaminoacridine or THA) for treatment of senile dementia. Warner-Lambert has expressed interest in developing the cholinergic agent, which was first marketed in the 1930s. The Senate Labor & Human Resources Committee member noted that tacrine achieved a 92% success rate in a private study conducted in 19 patients and published last fall in the New England Journal of Medicine.
|
Sen. Pell (D-R.I.) introduced legislation to require the National
Institute on Aging to provide $2 mil. per year for a three-year
study of tacrine (tetrahydroaminoacridine or THA) for treatment of
senile dementia. Warner-Lambert has expressed interest in
developing the cholinergic agent, which was first marketed in the
1930s. The Senate Labor & Human Resources Committee member
noted that tacrine achieved a 92% success rate in a private study
conducted in 19 patients and published last fall in the New
England Journal of Medicine.
|